Moderna CEO calls 2023 ‘difficult year.’ Here’s why 2024 could bring new hope.

After barely beating its 2023 vaccine-sales outlook, which Moderna had previously adjusted down, the Cambridge company is gearing up for a future beyond Covid-19 vaccines.